Aeovian Pharmaceuticals

selective mTORC1 inhibition, CD38 inhibition, small molecules

modulatingsmall molecule

aeovian.com·2930 Domingo Avenue #145, Berkeley, CA 94705·$234M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-ITGT

Projects

CD38 modulator program

exploratory

drug program · medium · Wed Apr 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop CD38 modulators and uses thereof for therapeutic applications, including disease treatment and modulation of target-cell responses such as reduced proliferation or down-regulation of target protein activity.

Patent-disclosed compounds or salts described as CD38 modulators, including heterocycle-containing chemical matter.

European patent application EP4532483A1 published and listed as pending.

AV078 mTORC1 inhibitor program

phase 1

drug program · high · Wed Jan 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Evaluate AV078 as a selective mTORC1 inhibitor, with relevance to rare genetic and age-related diseases involving dysregulated growth or hyperactive signaling.

Phase 1 clinical trial in healthy adult volunteers assessing safety, tolerability, pharmacokinetics, single ascending doses, multiple ascending doses, food effects, and potential drug-drug interactions.

Phase 1 study planned to assess safety, tolerability, and pharmacokinetics in healthy volunteers.

Targeted small molecules to restore cellular metabolic quality control

undisclosed

platform · medium

Restore cellular metabolic quality control to address dysregulated growth and hyperactive signaling in certain rare genetic and age-related diseases.

Development of targeted and highly selective small-molecule therapeutics.

Company described as clinical-stage, but no specific trial phase or program milestone is provided in the supplied material.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence